

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: Laura Aykroyd (Total Healthcare Group); Kim W. Benner (ASHP, Alabama Society of Health-System Pharmacists, Pediatric Pharmacy Advocacy Group); Elizabeth Anne Farrington (Pediatric Pharmacy Advocacy Group Board, Pediatric Nurse Practitioner Certification Board); Shannon W. Finks (Novartis Pharmaceuticals); Tracy Hagemann (Lexi-Comp, Inc.); Brian A. Hemstreet (Conexus Health); David S. Hoff (Children's HeartLink, Anesiva, Inc., ZymoGenetics, Inc.); Lisa C. Hutchison (Arkansas Medicaid, Arkansas Foundation for Medical Care); Claudia Kamper (Integrus Health); Donna M. Kraus (Discovery Labs [self], Trius Therapeutics, Cempra Pharmaceuticals, Johnson & Johnson, RIB-X, Baxter, Pfizer, GSK Pharmaceuticals, Targanta Therapeutics, Theravance, HGB, Astellas Pharma, Achaogen Pharmaceuticals [spouse or significant other]); Robert J. Kuhn (UnitedHealth Pharmaceutical Solutions); Michelle Richardson (Amgen, QualityMetric); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, *Annals of Pharmacotherapy*); Jeffrey T. Sherer (Sturge-Weber Foundation);

Stock Ownership: Laura Aykroyd (Pfizer, Procter & Gamble); Katherine H. Chessman (Procter & Gamble [spouse or significant other]); Lisa C. Hutchison (Cardinal Health); Darius Mason (Walgreens);

Royalties: Lisa C. Hutchison (ASHP); Donna M. Kraus (Lexi-Comp, Inc. [self], Humana Press [spouse or significant other]);

Grants: Gilbert J. Burckart (FDA); Brian A. Hemstreet (AstraZeneca); Anne Hume (AHRQ [two grants], HRSA); Lisa C. Hutchison (Boehringer Ingelheim, National Institutes of Health); Mary Jayne Kennedy (National Institutes of Health, A.D. Williams Foundation, Genentech, Inc., Kosair Charities, U.S. Department of Energy, National Institute

of Child Health and Human Development [two grants], Department of Pediatrics Intradepartmental Clinical Research Grant); Chad A. Knoderer (Cook Medical, Novartis [spouse or significant other], ASHP Foundation); Donna M. Kraus (Johnson & Johnson [two grants, spouse or significant other]); Robert J. Kuhn (Novartis); Carisa J. Schweitzer Masek (Novartis); Jennifer L. Morris (ASHP Foundation); Michael D. Reed (Cereza, Purdue Pharma, Hattie Larlham); Michelle Richardson (NIH NIDDK [two grants]); Winnie Seto (Canadian Institute of Health Research);

Honoraria: Lea S. Eiland (Astellas Pharma, Cubist Pharmaceuticals, Wyeth Pharmaceuticals); David S. Hoff (Pediatric Pharmacy Advocacy Group); Lisa C. Hutchison (ACCP, ASHP); Donna M. Kraus (Johnson & Johnson, AstraZeneca, Astellas Pharma, Wyeth Pharmaceuticals, Schering-Plough [spouse or significant other]); Michael D. Reed (Enzon Pharmaceuticals); Michelle Richardson (Amgen);

Other:

Nothing to Disclose: Clarence Chant, Agnes Chou, Mark R. Haase, Carol Heunisch, Kellie L. Knight, Kelley R. Lee, Marianne McCollum, Milap C. Nahata, Vinita B. Pai, Kalen B. Porter, Tracy Sandritter, Christopher L. Shaffer, Jim Thigpen.

ROLE OF ACCP: ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmacy Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

ROLE OF BPS: The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at www.bpsweb.org/recertification/general.cfm.

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties
2215 Constitution Avenue NW
Washington, DC 20037
(202) 429-7591
www.bpsweb.org